BFA
PGNX

BlackRock Fund Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

BlackRock Fund Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$27.8M Buy
3,219,577
+360,423
+13% +$2.66M 0.01% 1997
2016
Q3 		$18.1M Buy
2,859,154
+139,469
+5% +$843K ﹤0.01% 2124
2016
Q2 		$11.5M Sell
2,719,685
-6,111
-0.2% -$29.5K ﹤0.01% 2325
2016
Q1 		$11.9M Buy
2,725,796
+21,002
+0.8% +$93.5K ﹤0.01% 2268
2015
Q4 		$16.6M Sell
2,704,794
-135,302
-5% -$887K ﹤0.01% 2160
2015
Q3 		$16.2M Buy
2,840,096
+99,942
+4% +$767K ﹤0.01% 2124
2015
Q2 		$20.4M Sell
2,740,154
-53,252
-2% -$322K ﹤0.01% 2103
2015
Q1 		$16.7M Buy
2,793,406
+48,237
+2% +$304K ﹤0.01% 2165
2014
Q4 		$20.8M Buy
2,745,169
+228,202
+9% +$1.37M 0.01% 2051
2014
Q3 		$13.1M Sell
2,516,967
-77,873
-3% -$388K ﹤0.01% 2200
2014
Q2 		$11.2M Sell
2,594,840
-166,489
-6% -$636K ﹤0.01% 2353
2014
Q1 		$11.3M Buy
2,761,329
+428,364
+18% +$2.19M ﹤0.01% 2331
2013
Q4 		$12.4M Sell
2,332,965
-40,591
-2% -$179K ﹤0.01% 2256
2013
Q3 		$11.9M Buy
2,373,556
+644,556
+37% +$3.5M ﹤0.01% 2249
2013
Q2 		$7.71M Buy
+1,729,000
New +$7.76M ﹤0.01% 2424

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return

BlackRock Fund Advisors's PGNX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Progenics Pharmaceuticals Inc (PGNX) stake by 13% in Q4 2016, buying an estimated $2.66M and bringing the position to 3,219,577 shares worth $27.8M. The position accounts for 0.01% of the portfolio, ranked #1997.

BlackRock Fund Advisors first reported a position in PGNX in Q2 2013 and has held it in 15 quarters since. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • BlackRock Fund Advisors held 3,219,577 shares of Progenics Pharmaceuticals Inc worth $27.8M as of Q4 2016.
  • BlackRock Fund Advisors bought 360,423 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $2.66M.
  • Progenics Pharmaceuticals Inc made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1997 holding.
  • BlackRock Fund Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and has held it in 15 quarters since.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.